VT's Grumpies and Lady Discuss the U.S. Biotech Policy Landscape
Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two Vital Transformation colleagues on biopharma pricing policy, market access, and innovation risk:
Gwen O'Loughlin: Research Partner at Vital Transformation
Harry Bowen: Consulting Economist at Vital Transformation
They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.